Biofrontera Inc. Announces Results From Phase 1 Safety Study Evaluating Photodynamic Therapy With Three Tubes Of Ameluz
Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces positive topline results from its non-randomized,